|Chemical and physical data|
|Molar mass||143.87 kg/mol|
|(what is this?)|
Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and other inflammatory diseases. Tralokinumab was discovered by Cambridge Antibody Technology scientists, using Ribosome Display, as CAT-354 and taken through pre-clinical and early clinical development. After 2007 it has been developed by MedImmune, a member of the AstraZeneca group, where it is currently in Ph3 testing for asthma and Ph2b testing for atopic dermatitis. This makes it one of the few fully internally discovered and developed drug candidates in AstraZeneca's late stage development pipeline.
Discovery and Development
Tralokinumab (CAT-354) was discovered by Cambridge Antibody Technology scientists using protein optimization based on Ribosome Display. They used the extensive data sets from ribosome display to patent protect CAT-354 in a world-first of sequence-activity-relationship claims. In 2004, clinical development of CAT-354 was initiated with this first study completing in 2005. On 21 July 2011, MedImmune LLC initiated a Ph2b, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma.
As of 2016, MedImmune and AstraZeneca are developing tralokinumab for asthma (Ph3) and atopic dermatitis (Ph2b) while clinical development for moderate-to-severe ulcerative colitis and idiopathic pulmonary fibrosis (IPF) have been discontinued.
Tralokinumab was licensed to LEO Pharma for skin diseases in July 2016. 
- Kopf, Manfred; Bachmann, Martin F.; Marsland, Benjamin J. (2010). "Averting inflammation by targeting the cytokine environment". Nature Reviews Drug Discovery. 9 (9): 703–18. PMID 20811382. doi:10.1038/nrd2805.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab" (PDF). American Medical Association.
- Thom, G; Cockroft, AC; Buchanan, AG; Candotti, CJ; Cohen, ES; Lowne, D; Monk; Shorrock-Hart, CP; Jermutus, L; Minter, RR. "Probing a protein–protein interaction by in vitro evolution" [P]. Proc. Natl. Acad. Sci. USA. 103: 7619–7624. PMC . PMID 16684878. doi:10.1073/pnas.0602341103.
- May, RD; Monk, PD; Cohen, ES; Manuel, D; Dempsey, F; Davis, NHE; Dodd, AJ; Corkill, DJ; et al. (2012). "Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma". British Journal of Pharmacology. 166 (1): 177–193. PMC . PMID 21895629. doi:10.1111/j.1476-5381.2011.01659.x.
- "Pipeline". MedImmune. Retrieved 11 June 2013.
- "Studies found for CAT-354". ClinicalTrials.gov. Retrieved 11 June 2013.
- Human Antibody Molecules for Il-13, retrieved 2015-07-26
- Jermutus, Lutz; Honegger, Annemarie; Schwesinger, Falk; Hanes, Jozef; Plückthun, Andreas (2001-01-02). "Tailoring in vitro evolution for protein affinity or stability". Proceedings of the National Academy of Sciences. 98 (1): 75–80. ISSN 0027-8424. PMC . PMID 11134506. doi:10.1073/pnas.98.1.75.
- "Tralokinumab - AdisInsight". adisinsight.springer.com. Retrieved 2016-02-20.
- Clinical trial number NCT01402986 for "A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma" at ClinicalTrials.gov
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|